Dr. Neville's fellowship is again a clear indication that microbiologists are making the effort to get PBT2 to the market, not the neurodegeneration specialists of ATH. I am sure there will be more to come, urinary infections would be a good target, IMO. In spite of Dr. Neville being from Melbourne, she is a part of the Queensland microbiology group, and sure she will be supported also by that team and perhaps also by Uniquest.
ATH Price at posting:
2.0¢ Sentiment: None Disclosure: Held
